No Data
No Data
We Think Cullinan Therapeutics (NASDAQ:CGEM) Can Afford To Drive Business Growth
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $29 to $36
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
Cullinan Oncology Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $33
Cullinan Therapeutics Analyst Ratings
just a normal fella : your supposed to be resting… doctors orders!!